Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 27 to 23.2.
Financials
Financial year 2025
NOBEL BIOCARE BELGIUM from Mechelen, company number BE0864916237, closed financial year 2025 with a result of € 552,002 after tax. For that financial year NOBEL BIOCARE BELGIUM recorded revenue of € 25.9 million and equity of € 6.6 million. Compared with financial year 2024, the result moved from € 381,160 to € 552,002. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 6.6 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 552,002
▲ 45% vs 2024
Profit after tax over the fiscal year.
€ 8.6 million
▼ 26% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 6.5 million.
People and assets in 2025
23.2
▼ 2.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4 million
▲ 3% vs 2024
€ 174,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 18,424
▲ 87% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5.4 million
▼ 43% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 92 days on average.
€ 1.4 million
▲ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 22,826,945 | € 26,501,354 | € 24,897,388 | € 25,917,239 | ▲ 4% |
| Profit after taxes | € 282,858 | € 387,003 | € 381,160 | € 552,002 | ▲ 45% |
| Equity | € 4,837,380 | € 5,224,383 | € 6,048,323 | € 6,600,325 | ▲ 9% |
| Total debts | € 4,435,226 | € 8,369,312 | € 11,104,743 | € 7,447,937 | ▼ 33% |
| Cash | € 4,972,152 | € 7,254,276 | € 11,586,172 | € 8,624,993 | ▼ 26% |
| Retained profit | € 4,699,737 | € 5,086,740 | € 5,910,680 | € 6,462,682 | ▲ 9% |
| Balance sheet total | € 9,272,606 | € 13,593,694 | € 17,153,966 | € 14,048,262 | ▼ 18% |
| Employees (FTE) | 29.1 | 27 | 25.8 | 23.2 | ▼ 2.6 |
Key figures of NOBEL BIOCARE BELGIUM, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NOBEL BIOCARE BELGIUM?
What happened at NOBEL BIOCARE BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Patrick Perret stepped down as director. NBB
- Grégory Ben Fredj stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 552,002 (▲ 45% vs 2024). Source: NBB ↗
- Rudy Jacquemijn stepped down as director. NBB
- Patrick Perret became a director. NBB
- Grégory Ben Fredj became a director. NBB
- Rudy Jacquemijn became a director. NBB
- New establishment in Mechelen. KBO
In short
From € 282,858 profit in 2021 to € 552,002 profit in 2025.
Paid € 778,084 in corporate taxes since 2021.
Best year ever: 2025, with € 552,002 profit.
Pays suppliers within 92 days on average.
A new publication or filing at NOBEL BIOCARE BELGIUM? We notify you, reason included.
Follow NOBEL BIOCARE BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Grégory Ben Fredj
Gedeleerd bestuurder
since 2023 · until 2028
Rudy Jacquemijn
bestuurder
since 2013 · until 2025
Patrick Perret
bestuurder
since 2024 · until 2029
Establishments
Establishment units
Physical locations of this company
Stationsstraat 102-108
2800 Mechelen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
FASTLY - Fastly, Inc., US
Website info
Features
Security
Network
Details
- Company number
- 0864.916.237
- VAT number
- BE 0864.916.237
- Registered office
- Stationsstraat 102-108, 2800 Mechelen
- Names & denominations
- NOBEL BIOCARE BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 April 2004
- Peppol
- Active · Active since 29 Dec 2025
- Contact
- nobelbiocare.com
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden